RecruitingPhase 2NCT06745063

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Sponsor

VA Office of Research and Development

Enrollment

50 participants

Start Date

May 30, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity Vascular Health

Summary

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

Eligibility

Min Age: 30 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Empagliflozin and a drug called Placebo for people with obesity and vascular health. The study is currently recruiting participants at 1 location. People eligible for this study include aged 30 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.